S-145

S-145 is a synthetic compound that acts as a selective agonist for the prostanoid receptor subtype known as the IP receptor. It is primarily used in research settings to study the physiological and pharmacological roles of prostacyclin (PGI2) and its receptor in various biological systems.

Pharmacology

S-145 is known for its high selectivity and potency as an IP receptor agonist. The activation of the IP receptor by S-145 leads to a cascade of intracellular events, primarily involving the increase of cAMP levels, which results in various physiological effects such as vasodilation, inhibition of platelet aggregation, and modulation of inflammatory responses.

Mechanism of Action

S-145 binds to the IP receptor, a G-protein coupled receptor (GPCR), which is coupled to the Gs protein. Upon activation, the Gs protein stimulates adenylate cyclase, leading to an increase in cAMP production. Elevated cAMP levels activate PKA, which then phosphorylates target proteins to exert its effects.

Therapeutic Potential

While S-145 itself is not used therapeutically, its role as a research tool has provided insights into the potential therapeutic applications of IP receptor agonists. These include the treatment of pulmonary arterial hypertension, prevention of thrombosis, and management of inflammatory diseases.

Research Applications

S-145 is extensively used in preclinical studies to:

• Investigate the role of prostacyclin in cardiovascular physiology.
• Explore the anti-inflammatory effects of IP receptor activation.
• Study the molecular pathways involved in IP receptor signaling.

Safety and Toxicology

As a research compound, S-145 is typically used in controlled laboratory settings. Its safety profile in humans is not well-documented, and it is not approved for clinical use.

Also see

• Prostacyclin
• Prostaglandin receptors
• Vasodilation
• Platelet aggregation